Johnson & Johnson reports 1.6% drop in Q2 orthopedics sales to $2.2B: 5 things to know

Laura Dyrda -   Print  |

Johnson & Jonson medical devices segment reported a 6.9 percent sales decrease in the second quarter to $6.4 billion.

U.S. sales medical device sales dropped 5.6 percent in the second quarter to $3 billion during the quarter.

Five things to know about Johnson & Johnson's orthopedics sales:

1. Overall, second quarter orthopedics sales dropped 1.6 percent to $2.2 billion. U.S. sales were flat at $1.3 billion and international sales dropped 3.8 percent to $894 million. Worldwide orthopedic sales at the six months end dropped 2 percent to $4.4 billion.

2. Worldwide hip sales were up 0.9 percent to $364 million. U.S. hip sales jumped 2.1 percent to $216 million while international sales dropped slightly to $147 million.

3. U.S. knee sales decreased 4.8 percent to $218 million while international knee sales were flat at $153 million. Worldwide knee sales were down 2.8 percent to $372 million.

4. The international spine and other segment sales dipped 5.3 percent in the second quarter to $328 million, while U.S. spine sales dropped 1.5 percent to $490 million. Worldwide, the company reported a 3.1 percent drop in spine sales to $818 million.

5. Orthopedic trauma sales dipped 0.6 percent to $672 million worldwide. U.S. orthopedic trauma sales increased 3.3 percent to $407 million while international sales declined 5.9 percent to $265 million.

More articles on orthopedic devices:
34 orthopedic, spine devices receive FDA 510(k) clearance in June
Medtronic, Smith & Nephew & more: 10 device company notes
Medtronic secures market position through Titan Spine acquisition, analyst says

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers